Investigational Combination of First-in-Class Bispecific Antibodies TALVEY®▼ (Talquetamab) and TECVAYLI®▼ (Teclistamab) Shows Deep and Durable Responses in Heavily Pretreated Multiple Myeloma Patients with Extramedullary Disease

Janssen-Cilag International NV announced new results from the Phase II RedirecTT-1 study evaluating the investigational combination of TALVEY^®▼(talquetamab), the first European Commission (EC) approved GPRC5D-directed bispecific antibody, and TECVAYLI^®▼(teclistamab), the first EC-approved BCMA-directed bispecific antibody.